. Anterior focal endophthalmitis presented with an inflammatory nodule in the iris extending from the ciliary body retina with perivascular hemorrhages in the early stages of the disease. (26) As the infection progresses, the retina becomes necrotic, and vitreous abscess frequently occur. (26) (Fig. 7) The anterior segment is also involved with forward spread of the infection and hypopyon is formed as the disease progresses. (26) (Fig. 8 ) The intraocular pressure is low. (26) The poor visual prognosis is most likely due to retinal ischemia as a result of occlusion of central retinal artery by a septic embolus. (26) Panophthalmitis is inflammation of all coats of the eye including intraocular structures. (27) (28) (29) It presents with marked lid edema, proptosis and limitation of ocular movements. (28) (Fig. 9 ) All details of anterior as well as posterior chamber are lost because of the prominent hypopyon. (29) (Fig. 10 ) Typically the intraocular pressure is high. (29) It is a disastrous and rapidly developing infection that destroys the globe and invades the orbit, resulting in blindness, phthisis or enucleation. (28, 29) Depending of the virulence of pathogen, progression of panophthalmitis may be life threatening. (28) 
Pathogenesis
In endogenous endophthalmitis the microorganisms enter into the uveal tract or retinal circulation as scattered organisms or in a bolus, and lodge in small capillaries. (30, 31) To invade ocular tissues and produce infection the organisms must cross the blood-ocular barrier either by direct invasion (septic emboli) or by changes in vascular endothelium caused by substrates released during infection. (30) They establish a septic focus that can develop in the retina prior to breaking into the vitreous. (30) The infectious embolus is usually in proximity to the retinal vessels. (30) If a large septic embolus pass through the www.intechopen.com central retinal artery and disseminates throughout the retina, retinal necrosis and ischemia may occur. (30) This allows the microorganisms to quickly invade the vitreous and further the anterior segment, causing inflammation of intraocular tissues (panuveitis) that may be mixed-up a non-infectious inflammatory disease. (31) Similarly, in cases of fungal endophthalmitis a localized inflammatory reaction surrounding a small nidus of fungi forms in the inner choroid, breaks through Bruch's membrane into the retina forming a microabscess and spreads into the vitreous cavity. (31) It is a destructive process that has a poor visual prognosis that the visual loss rate reaches up to 37.5%. (30) The final visual outcome in patients with endogenous bacterial endophthalmitis in the recent 12 years has not differed significantly from five decades ago. (31) Under normal circumstances, the blood-ocular barrier provides a natural resistance against invading organisms. (30) Destruction of intraocular tissues may be due to direct invasion of the organism and/or from inflammatory mediators of the immune system. (30, 31) In any type of endophthalmitis, bacteria are introduced into the intraocular environment, encountering a site of immunological inactivity. (30) The intraocular environment is termed an "immune privileged site", devoid of inflammatory mediators and cells present that would otherwise fight infection. (32) The blood-ocular barrier facilitates maintenance of a sterile environment in the interior of the eye contributing to the immune privileged site. (32) In this environment initial immune responses that would typically handle infection are delayed or absent, providing an optimum growth medium for the organisms that reach the area. (32) Eventually, organisms are recognized and inflammation initiates in an effort to handle the infection. (30) The extent of inflammation in the eye is during endophthalmitis has been shown to be organism dependent. (30, 31) The course of endophthalmitis, treatment effectiveness and visual outcome can be unpredictable. (33) Clinical presentation of the disease depends, in part, on the relative virulence of the infecting pathogen, the mechanism of introduction into the eye and how quickly treatment is initiated. (33) Other factors that affect the outcome of infection include the patients' age, how vulnerable the infecting agent is to antibiotic therapy and the anatomic condition of the eye during infection. (33) Clinical studies have reported that increased time between infection and treatment is associated with a worse visual outcome. (19, 34) Endophthalmitis may be as subtle as white nodules on the lens capsule, iris, retina, or choroid. (35) It can also be as ubiquitous as inflammation of all the ocular tissues, leading to a globe full of purulent exudate. (36) In addition, inflammation can spread to involve the orbital soft tissue. (37) 
Mortality/morbidity
Decreased vision and permanent loss of vision are common complications of endophthalmitis. (33, 34) Patients may require enucleation to eradicate a blind and painful eye. (38) Mortality is related to the patient's comorbidities and the underlying medical problem, especially when considering the etiology of hematogenous spread in endogenous infections. (39, 40) 
Clinical presentations
Bacterial endophthalmitis usually presents acutely with pain, redness, lid swelling, and decreased visual acuity. (11, 16, 22) 
Causes
Individuals at risk for developing endogenous endophthalmitis usually have comorbidities that predispose them to infection. These include conditions like diabetes mellitus, chronic renal failure, cardiac valvular disorders, prosthetic heart valves, systemic lupus erythematosus, AIDS, leukemia, gastrointestinal malignancies, neutropenia, lymphoma, alcoholic hepatitis, intravenous drug abuse, and bone marrow transplantation. (50, 51) Sources of endophthalmitis include most commonly endocarditis followed by urinary tract infection, wound infection and meningitis. (4) Additionally, pharyngitis, pulmonary infection, septic arthritis, pyelonephritis and intraabdominal abscess have also been implicated as sources of infection. (10) About 25% of the cases are bilateral and usually caused by Meningococcus, E.coli and Klebsiella species. (52, 53) The most common cause in two-thirds of the infections is Gram-positive bacteria. (31, 33) Although the most common agent was S.aureus (25% of patients), the most common group was streptococcus (32%). (31, 33) Endogenous endophthalmitis in adults caused by group B Streptococcus has been reported rarely and is almost exclusively related to infective endocarditis. (7,54) Gramnegative organisms cause 32-37% of all endogenous endophthalmitis cases and typically have poor visual outcomes because these infections are difficult to treat. (5, 55, 56) The low prevalence of Gram-negative bacteria amongst the causative organisms of both infective endocarditis and endogenous endophthalmitis might be related to the absence of an outer capsule, which makes them sensitive to complement mediated lysis and other humoral innate immune defenses, and the lack of surface proteins that specifically bind host matrix molecules and prosthetic material. (57) Moreover, a much higher inoculums of Gramnegative than Gram-positive organisms is required to induce infective endocarditis in laboratory animals. (57) Although aggressive therapy was given, the visual prognosis for all these patients was poor. (56,57) E. coli emphysematous endophthalmitis is a very rare and severe variety of E. coli endophthalmitis. (58, 59) The mechanism of emphysematous endophthalmitis has been postulated that a high concentration of glucose in the eye tissue may provide a substrate that bacteria can ferment to produce carbondioxide and hydrogen. 
Diagnosis
The high incidence of misdiagnosis of endogenous endophthalmitis ranging from conjunctivitis, acute glaucoma or other ocular conditions should alert the ophthalmologist to make a correct diagnosis of this insidious entity. The possibility of endogenous endophthalmitis should be considered in any patient who manifests a pronounced anterior reaction that is refractory to steroid treatment. The appropriate diagnosis is necessary to start the appropriate treatment and influence dramatically the visual outcome as well as reduce the incidence of systemic complications, sometime fatal. Therefore the crucial point is diagnostic suspicion. The diagnostic algorithm should include accurate ocular and systemic history, investigation of risk factors, search source of infection, fluorescein angiography, (Fig. 12 ) B/A scan ocular ultrasonography, (Fig. 13 ) and computerized tomography of the orbit (Fig. 14) Apart from microbiological investigation, other tests may be required according to the clinical picture. These would include complete blood cell count with differential, erythrocyte sedimentation rate, blood urea nitrogen and creatinine.
Differential diagnosis
Endogenous endophthalmitis should always be considered early in the differential diagnosis of anterior uveitis. (87) The common causes of anterior uveitis must be excluded by the usual serological tests. (87) Glaucoma, CMV retinitis, toxoplasma chorioretinitis, primary intraocular lymphoma, syphilitic chorioretinitis, autoimmune causes, malignancies, masquerade, metastatic tumors, and other infectious diseases should also be ruled out. (93) Rarely, cavernous sinus thrombosis, corneal abrasion, corneal laceration, corneal ulceration and ulcerative keratitis, globe rupture, herpes zoster ophthalmicus and vitreous hemorrhage are included in the differential diagnosis. (78, 94) 9. Medical treatment
Systemic therapy
Prompt administration of antibiotic therapy is the key in the acute management of endogenous endophthalmitis. Systemic antibiotics also treat distant foci of infection and prevent continued bacteremia, thereby reducing the chances of invasion of the unaffected eye. Prolonged intravenous therapy is usually required for 2-4 weeks, until it is certain that the systemic infection is eradicated. (33) Empiric broad-spectrum antibiotic therapy with vancomycin and aminoglycoside or a third-generation cephalosporin is recommended at the highest theurapeutic doses. (33, 52) Gentamycine has the coverage of gram-negative organisms including Pseudomonas aeruginosa. (25, 44) It is the first choice aminoglycoside for systemic gram-negative coverage. (25, 44) 
Intravitreal therapy
Although the value of intravitreal antibiotics over and above the use of intravenous antibiotics has not been definitively established, most cases in our experience are of posterior diffuse disease and panophthalmitis which denote severe infection with extension of organisms into the vitreous. These cases should be treated aggressively as possible with both systemic and intravitreal antibiotics. In cases caused by bacteria, intravitreal injection of vancomycin 1mg/0.1ml and ceftazidime 2mg/0.1 ml provides good coverage and avoids the toxicity associated with aminoglycosides. (41, 108) Repeated injections may be required since the half-life of these drugs in the vitreous cavity is short. (108) In most cases of fungal endophthalmitis, an intravitreal injection of 5-10 microgram amphotericin B is recommended. (103) Using amphotericin B in this manner avoids its numerous systemic side effects, but its potential for retinal toxicity should be noted. (103) The use of intravitreal, topical and subtenon steroids should be avoided in fungal endophthalmitis. (99) However, the use of intravitreal steroid, dexamethasone in addition to intravitreal antibiotics is recommended for suppression of inflammatory mediators released in the vitreous in bacterial endophthalmitis. (108) (109) (110) (111) The histopathological changes of the eyes treated with intravitreal vancomycin with dexamethasone (0.4 mg/ml) had less conjunctival inflammation, mild iridocyclitis, less vitreous cells, less choroidal vasculitis and retinitis compared to antibiotic treatment alone. (109, 110) Topical steroids are also used in patients with anterior focal or diffuse endophthalmitis to reduce the number of inflammatory cells in the anterior chamber, thereby preventing the complications such as formation of synechiae and secondary glaucoma. (112) (113) (114) Topical antibiotics are definitively indicated if keratitis develops and adjunctive therapy includes the use of cycloplegics, ocular hypotensives and topical steroids. (113,114) 
Surgical treatment
The timing of and necessity for vitrectomy remains unclear in endogenous endophthalmitis. (115, 116) The benefits of vitreous tap outweigh the benefits of vitrectomy for anterior focal or diffuse and posterior focal cases with endogenous endophthalmitis. (38) In general vitrectomy is indicated in cases of posterior diffuse cases with prominent vitreous involvement, and also for cases showing progressive disease despite intensive medical therapy. (116) In these cases small gauge vitrectomy is effective in clearing the vitreous from the inflammatory debris, cells and mediators. (117) Other advantage includes the possibility to have larger sample to make the diagnosis and also to deliver a therapeutic level of drug in the vitreous. (118, 119) In these cases vitrectomy and intravitreal antibiotics may, however, prevent ocular atrophy or the necessity for enucleation. (119) 
Prognosis
The visual outcome is usually good in the anterior form of endophthalmitis, differently from posterior diffuse and panophthalmitis forms. 
Conclusion
Endogenous endophthalmitis continues to occur among the patients with infective endocarditis despite the continuing development of effective antibiotics. Although it is devastating, vision can sometimes be salvaged, especially if diagnosis is made early and prompt systemic therapy instituted. The role of intravitreal antibiotics and vitrectomy is not well defined but they have a definite role in cases which progress despite medical therapy and also where fungi are implicated. Future challenge ahead include the aging population and the development of new microbial antibiotic resistance. A coordinated multidisciplinary effort will be required to keep abreast of this difficult condition.
